Global Insulin Delivery Systems Market 2016-2020

  • ID: 3832430
  • Report
  • Region: Global
  • 81 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Animas
  • Cellnovo
  • Debiotech
  • MannKind
  • Owen Mumford
  • SOOIL
  • MORE
About Insulin

The cost of syringes and insulin pens is low, which enables users to opt for them as first choice devices. High cost of insulin pumps and insulin jet injectors poses a challenge to the growth of the market. Insulin pumps and jet injectors also require special care and maintenance, which is an additional cost burden to patients.

The analysts forecast the global insulin delivery systems market to grow at a CAGR of 5.11% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global insulin delivery systems market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sale of insulin delivery systems.

The market is divided into the following segments based on geography:

- Americas
- APAC
- EMEA

The report, Global Insulin Delivery Systems Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Novo Nordisk
- Sanofi
- BD
- Eli Lilly
- Medtronic

Other prominent vendors
- Animas
- Beta Bionics
- Cellnovo
- Copernicus
- Dance Biopharm
- Debiotech
- InsuJet
- Insulet
- MannKind
- Owen Mumford
- Roche
- SHL
- SOOIL
- Tandem Diabetes Care
- Valeritas
- West Pharma
- Ypsomed

Market drivers
- Paradigm shift of patient pool from hospitals to specialty clinics

Market challenges
- High cost of insulin devices and competitive pricing scenario

Market trends
- Inhalers to revolutionize insulin delivery

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Animas
  • Cellnovo
  • Debiotech
  • MannKind
  • Owen Mumford
  • SOOIL
  • MORE
PART 01: Executive summary
  • Highlights
PART 02: Scope of the report
  • Market overview
  • Top vendor offerings
PART 03: Market research methodology
  • Research methodology
  • Economic indicators
PART 04: Introduction
  • Key market highlights
PART 05: Market landscape
  • Market overview
  • Market size and forecast
  • Five forces analysis
PART 06: Market segmentation by product
  • Global insulin syringes market
  • Global insulin pumps market
  • Global insulin pens market
  • Global insulin jet injectors market
PART 07: Market segmentation by end-user
  • Hospitals
  • Specialty diabetic clinics
  • Retail channels
PART 08: Geographical segmentation
  • Insulin delivery systems market in Americas
  • Insulin delivery systems market in EMEA
  • Insulin delivery systems market in APAC
PART 09: Market drivers
  • Increase in type-1 diabetes
  • Paradigm shift of patient pool from hospitals to specialty clinics
  • Focus on self-management of diabetes
PART 10: Impact of drivers

PART 11: Market challenges
  • High cost of insulin devices and competitive pricing scenario
  • Threat of substitutes
  • Budget restrictions and stringent reimbursement policies
  • Complications and unmet needs
PART 12: Impact of drivers and challenges

PART 13: Market trends
  • Inhalers to revolutionize insulin delivery
  • Disruptive technologies
  • Strategic alliances leading to innovative insulin delivery systems
PART 14: Vendor landscape
  • Competitive scenario
  • Recent developments
PART 15: Key vendor analysis
  • Novo Nordisk
  • Sanofi
  • BD
  • Eli Lilly
  • Medtronic
  • Other prominent vendors
PART 16: Appendix
  • List of abbreviations
PART 17: About the Author

List of Exhibits

Exhibit 01: Global insulin delivery systems market
Exhibit 02: Segment overview
Exhibit 03: Product offerings
Exhibit 04: Global insulin delivery systems market 2015-2020 ($ billions)
Exhibit 05: Five forces analysis
Exhibit 06: Product lifecycle of insulin delivery systems
Exhibit 07: Global insulin delivery systems market by product 2015
Exhibit 08: Global insulin delivery systems market by product 2020
Exhibit 09: Global insulin syringes market: Opportunity analysis
Exhibit 10: Global insulin syringes market: Metric analysis
Exhibit 11: Global insulin syringes market 2015-2020 ($ billions)
Exhibit 12: Global insulin pumps market: Opportunity analysis
Exhibit 13: Global insulin pumps market: Metric analysis
Exhibit 14: Global insulin pumps market 2015-2020 ($ billions)
Exhibit 15: Factors considered for making an ideal pen
Exhibit 16: Global insulin pens market: Opportunity analysis
Exhibit 17: Global insulin pens market: Metric analysis
Exhibit 18: Global insulin pens market 2015-2020 ($ billions)
Exhibit 19: Global insulin jet injectors market: Opportunity analysis
Exhibit 20: Global insulin jet injectors market: Metric analysis
Exhibit 21: Global insulin jet injectors market 2015-2020 ($ billions)
Exhibit 22: Global insulin delivery systems market by geography 2015
Exhibit 23: Global insulin delivery systems market by geography 2020
Exhibit 24: Global insulin delivery systems market by geography 2015-2020
Exhibit 25: Comparative study of diabetic population (0-14 years) in specific countries in Americas 2013 and 2015
Exhibit 26: Insulin delivery systems market in Americas 2015-2020 ($ billions)
Exhibit 27: Comparative study of diabetic population (0-14 years) in selected European countries 2013 and 2015
Exhibit 28: Comparative study of diabetic population (0-14 years) in selected MEA countries 2013 and 2015
Exhibit 29: Insulin delivery systems market in EMEA 2015-2020 ($ billions)
Exhibit 30: Insulin delivery systems market in APAC 2015-2020 ($ billions)
Exhibit 31: Comparison of type 1 diabetes incidences 2013 and 2015
Exhibit 32: Impact of drivers
Exhibit 33: Impact of drivers and challenges
Exhibit 34: Global insulin delivery systems market: Competitive landscape 2015
Exhibit 35: Recent developments
Exhibit 36: Ranking of vendors 2015
Exhibit 37: Novo Nordisk: Metric analysis
Exhibit 38: Sanofi: Metric analysis
Exhibit 39: BD: Metric analysis
Exhibit 40: Eli Lilly: Metric analysis
Exhibit 41: Medtronic: Metric analysis
Exhibit 42: Other prominent vendors
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Animas
  • Cellnovo
  • Debiotech
  • MannKind
  • Owen Mumford
  • SOOIL
  • MORE
New Report Released: - Global Insulin Delivery Systems Market 2016-2020

The author of the report recognizes the following companies as the key players in the global insulin delivery systems market: Novo Nordisk, Sanofi, BD, Eli Lilly, and Medtronic.

Other Prominent Vendors in the market are: Animas, Beta Bionics, Cellnovo, Copernicus, Dance Biopharm, Debiotech, InsuJet¸ Insulet, MannKind, Owen Mumford, Roche¸ SHL, SOOIL, Tandem Diabetes Care, Valeritas, West Pharma¸ and Ypsomed.

Commenting on the report, an analyst from the research team said: “One of the key trends for market growth will be the presence of strategic alliances leading to innovative insulin delivery systems. In November 2015, Debiotech, the ARTORG Center for Biomedical Engineering Research of the University of Bern, and the Division of Endocrinology, Diabetes and Clinical Nutrition of the Bern University Hospital collaborated to develop a novel generation artificial pancreas for the personalized delivery of insulin with the accuracy of an MEMS based pump. The ambition is to create a substantial change in the treatment of diabetes and in the market for the artificial pancreas.”

According to the report, one of the key drivers for market growth will be to focus on self-management of diabetes. The adoption of insulin delivery systems for type-1 diabetes management has increased in recent years. The adoption rate is increasing due to factors such as awareness, health consciousness, and a marginal improvement of healthcare policies allowing some reimbursement for insulin delivery devices. The devices used in hospitals and specialty clinics are now being used in home care treatment by patients. This trend is seen largely because it helps save the visiting costs and fees of hospitals and clinics, and saves waiting time. In recent times, normal insulin injections are being used at home by patients with the guidance of a physician. Insulin pens, pumps, and jet injectors are handy and can be carried anywhere and can be used anytime. This flexibility has made insulin delivery device users opt for self-care diabetes management.

Further, the report states that this comes as an interesting challenge for the insulin delivery systems market, where governments are willing to encourage the usage of these devices, but with certain limitations like stringent reimbursement policies. Since these devices are expensive, and not everyone can afford it, governments have to intervene with reimbursements. For instance, reimbursement for insulin delivery devices is available in parts of the US, whereas in Australia, these devices are offered as part of the healthcare policy. Reimbursement policies are generally decided based on the healthcare budget of the country. Hence, countries like India and China, where the diabetic population is high, find it difficult to offer reimbursement for such expensive insulin delivery devices.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
- Novo Nordisk
- Sanofi
- BD
- Eli Lilly
- Medtronic
- Animas
- Beta Bionics
- Cellnovo
- Copernicus
- Dance Biopharm
- Debiotech
- InsuJet¸ Insulet
- MannKind
- Owen Mumford
- Roche¸ SHL
- SOOIL
- Tandem Diabetes Care
- Valeritas
- West Pharma
- Ypsomed
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll